Role of Semaphorin 3A in Kidney Development and Diseases

Kidney diseases are worldwide public health problems affecting millions of people. However, there are still limited therapeutic options against kidney diseases. Semaphorin 3A (SEMA3A) is a secreted and membrane-associated protein, which regulates diverse functions, including immune regulation, cell survival, migration and angiogenesis, thus involving in the several pathogeneses of diseases, including eyes and neurons, as well as kidneys. SEMA3A is expressed in podocytes and tubular cells in the normal adult kidney, and recent evidence has revealed that excess SEMA3A expression and the subsequent signaling pathway aggravate kidney injury in a variety of kidney diseases, including nephrotic syndrome, diabetic nephropathy, acute kidney injury, and chronic kidney disease. In addition, several reports have demonstrated that the inhibition of SEMA3A ameliorated kidney injury via a reduction in cell apoptosis, fibrosis and inflammation; thus, SEMA3A may be a potential therapeutic target for kidney diseases. In this review article, we summarized the current knowledge regarding the role of SEMA3A in kidney pathophysiology and their potential use in kidney diseases.

[1]  C. Hwangbo,et al.  RAS-stimulated release of exosomal miR-494-3p promotes the osteolytic bone metastasis of breast cancer cells , 2023, International journal of molecular medicine.

[2]  C. Matrone,et al.  Semaphorin 3A influences neuronal processes that are altered in patients with autism spectrum disorder: potential diagnostic and therapeutic implications , 2023, Neuroscience & Biobehavioral Reviews.

[3]  Yasuo Okumura,et al.  Intravenous Semaphorin 3A Administration Maintains Cardiac Contractility and Improves Electrical Remodeling in a Mouse Model of Isoproterenol-Induced Heart Failure. , 2023, International heart journal.

[4]  Qingli Chen,et al.  Sema3A inactivates the ERK/JNK signalling pathways to alleviate inflammation and oxidative stress in lipopolysaccharide-stimulated rat endothelial cells and lung tissues , 2023, Autoimmunity.

[5]  N. Florens.  Cardiorenal Syndrome: Ebony and Ivory , 2023, Diagnostics.

[6]  Nora Seliem,et al.  Serum metabolomic profiles and semaphorin-3A as biomarkers of diabetic retinopathy progression. , 2023, The Egyptian journal of immunology.

[7]  A. Staruschenko,et al.  Call for Papers: Podocyte Physiology and Pathophysiology. , 2023, American journal of physiology. Renal physiology.

[8]  B. Wu,et al.  Sema3A Drives Alternative Macrophage Activation in the Resolution of Periodontitis via PI3K/AKT/mTOR Signaling , 2023, Inflammation.

[9]  Yongping Guo,et al.  LncRNA TCF7 contributes to high glucose‐induced damage in human podocytes by up‐regulating SEMA3A via sponging miR‐16‐5p , 2022, Journal of diabetes investigation.

[10]  A. Beck‐Sickinger,et al.  Pinpointing the interaction site between semaphorin‐3A and its inhibitory peptide , 2022, Journal of peptide science : an official publication of the European Peptide Society.

[11]  M. Landray,et al.  Empagliflozin in Patients with Chronic Kidney Disease , 2022, The New England journal of medicine.

[12]  T. Tsunoda,et al.  The Sympathetic Nervous System Contributes to the Establishment of Pre-Metastatic Pulmonary Microenvironments , 2022, International journal of molecular sciences.

[13]  Yusuke Suzuki,et al.  Randomized, double-blind, placebo-controlled phase 3 study of bardoxolone methyl in patients with diabetic kidney disease: design and baseline characteristics of the AYAME study , 2022, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[14]  E. P. Kiseleva,et al.  Semaphorin 3A in the Immune System: Twenty Years of Study , 2022, Biochemistry (Moscow).

[15]  H. Hara,et al.  Efficacy of an Anti-Semaphorin 3A Neutralizing Antibody in a Male Experimental Retinal Vein Occlusion Mouse Model , 2022, Investigative ophthalmology & visual science.

[16]  Yi-Fei Dong,et al.  Inhibition of semaphorin-3a alleviates lipopolysaccharide-induced vascular injury. , 2022, Microvascular research.

[17]  Suyu Wang,et al.  KCNQ1OT1 inhibition alleviates high glucose-induced podocyte injury by adsorbing miR-23b-3p and regulating Sema3A , 2022, Clinical and Experimental Nephrology.

[18]  Kenji Tsuji,et al.  Semaporin3A-inhibitor ameliorates renal fibrosis through the regulation of JNK signaling. , 2021, American journal of physiology. Renal physiology.

[19]  A. Barzilai,et al.  Inhibition of Sema-3A Promotes Cell Migration, Axonal Growth, and Retinal Ganglion Cell Survival , 2021, Translational vision science & technology.

[20]  D. Rimar,et al.  Low Urine Secretion of Semaphorin3A in Lupus Patients with Proteinuria , 2021, Inflammation.

[21]  Grant D. Huang,et al.  Pentoxifylline in diabetic kidney disease (VA PTXRx): protocol for a pragmatic randomised controlled trial , 2021, BMJ Open.

[22]  J. Kellum,et al.  Acute kidney injury , 2021, Nature Reviews Disease Primers.

[23]  N. Samsu.  Diabetic Nephropathy: Challenges in Pathogenesis, Diagnosis, and Treatment , 2021, BioMed research international.

[24]  D. Siegel,et al.  Vinaxanthone inhibits Semaphorin3A induced axonal growth cone collapse in embryonic neurons but fails to block its growth promoting effects on adult neurons , 2021, Scientific Reports.

[25]  X. Bai,et al.  Architecture of the Sema3A/PlexinA4/Neuropilin tripartite complex , 2021, Nature Communications.

[26]  A. Ceriello,et al.  Diabetes and kidney disease: emphasis on treatment with SGLT-2 inhibitors and GLP-1 receptor agonists. , 2021, Metabolism: clinical and experimental.

[27]  P. Torabi-Parizi,et al.  The Role of Semaphorins and Their Receptors in Innate Immune Responses and Clinical Diseases of Acute Inflammation , 2021, Frontiers in Immunology.

[28]  I. Weissman,et al.  Semaphorin 3A mediated brain tumor stem cell proliferation and invasion in EGFRviii mutant gliomas , 2020, BMC Cancer.

[29]  A. Kazlauskas,et al.  A SEMA3 Signaling Pathway-Based Multi-Biomarker for Prediction of Glioma Patient Survival , 2020, International journal of molecular sciences.

[30]  J. McMurray,et al.  Dapagliflozin in Patients with Chronic Kidney Disease. , 2020, The New England journal of medicine.

[31]  Li Zhu,et al.  The Role of Semaphorins in Metabolic Disorders , 2020, International journal of molecular sciences.

[32]  H. Senturk,et al.  Curcumin and LOXblock-1 ameliorate ischemia-reperfusion induced inflammation and acute kidney injury by suppressing the semaphorin-plexin pathway. , 2020, Life sciences.

[33]  Kenji Tsuji,et al.  Semaphorin3A-Inhibitor Ameliorates Doxorubicin-Induced Podocyte Injury , 2020, International journal of molecular sciences.

[34]  A. Ortiz,et al.  Targeting the progression of chronic kidney disease , 2020, Nature Reviews Nephrology.

[35]  L. G. Vu,et al.  Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 , 2020, The Lancet.

[36]  Xiao-mei Li,et al.  Decreased Expression of Semaphorin 3A and Semaphorin 7A Levels and Its Association with Systemic Lupus Erythematosus , 2020, Immunological investigations.

[37]  X. Gou,et al.  Exosomes from human‐bone‐marrow‐derived mesenchymal stem cells protect against renal ischemia/reperfusion injury via transferring miR‐199a‐3p , 2019, Journal of cellular physiology.

[38]  Xiaojing Chu,et al.  miR‐15b‐5p ameliorated high glucose‐induced podocyte injury through repressing apoptosis, oxidative stress, and inflammatory responses by targeting Sema3A , 2019, Journal of cellular physiology.

[39]  G. Chertow,et al.  Effects of Selonsertib in Patients with Diabetic Kidney Disease. , 2019, Journal of the American Society of Nephrology : JASN.

[40]  M. Araz,et al.  The Prognostic Value of Serum Semaphorin3A and VEGF Levels in Patients with Metastatic Colorectal Cancer , 2019, Journal of Gastrointestinal Cancer.

[41]  G. Neufeld,et al.  Class-3 Semaphorins and Their Receptors: Potent Multifunctional Modulators of Tumor Progression , 2019, International journal of molecular sciences.

[42]  Haojia Wu,et al.  Advantages of Single-Nucleus over Single-Cell RNA Sequencing of Adult Kidney: Rare Cell Types and Novel Cell States Revealed in Fibrosis. , 2018, Journal of the American Society of Nephrology : JASN.

[43]  A. Sabag,et al.  Altered expression of regulatory molecules in the skin of psoriasis , 2018, Immunologic Research.

[44]  H. Okano,et al.  Astrocyte-Derived Exosomes Treated With a Semaphorin 3A Inhibitor Enhance Stroke Recovery via Prostaglandin D2 Synthase , 2018, Stroke.

[45]  Hongfei Zhao,et al.  Inhibition of semaphorin-3a suppresses lipopolysaccharide-induced acute kidney injury , 2018, Journal of Molecular Medicine.

[46]  Marcello Tonelli,et al.  The global burden of kidney disease and the sustainable development goals , 2018, Bulletin of the World Health Organization.

[47]  Hui Gao,et al.  Expression of circulating Semaphorin3A and its association with inflammation and bone destruction in rheumatoid arthritis , 2018, Clinical Rheumatology.

[48]  G. Neufeld,et al.  Semaphorin3A: A Potential Therapeutic Tool for Lupus Nephritis , 2018, Front. Immunol..

[49]  Chunhong Ma,et al.  Gpr97 Exacerbates AKI by Mediating Sema3A Signaling. , 2018, Journal of the American Society of Nephrology : JASN.

[50]  Da-wei Wu,et al.  Urinary semaphorin 3A as an early biomarker to predict contrast-induced acute kidney injury in patients undergoing percutaneous coronary intervention , 2018, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[51]  H. Okano,et al.  The Semaphorin 3A inhibitor SM-345431 preserves corneal nerve and epithelial integrity in a murine dry eye model , 2017, Scientific Reports.

[52]  N. Mostafa,et al.  Relationship Between Atrasentan Concentrations and Urinary Albumin to Creatinine Ratio in Western and Japanese Patients With Diabetic Nephropathy. , 2017, Clinical therapeutics.

[53]  Kenji Tsuji,et al.  The level of urinary semaphorin3A is associated with disease activity in patients with minimal change nephrotic syndrome , 2017, International journal of nephrology and renovascular disease.

[54]  M. Schellings,et al.  Sema3A promotes the resolution of cardiac inflammation after myocardial infarction , 2017, Basic Research in Cardiology.

[55]  R. Al-Temaimi,et al.  Assessment of plasma biomarkers for their association with Multiple Sclerosis progression , 2017, Journal of Neuroimmunology.

[56]  H. Florez,et al.  How to prevent the microvascular complications of type 2 diabetes beyond glucose control , 2017, British Medical Journal.

[57]  G. Reddy,et al.  Advanced glycation end products mediated cellular and molecular events in the pathology of diabetic nephropathy , 2016, Biomolecular concepts.

[58]  Mei Xue,et al.  Semaphorin 3A attenuates cardiac autonomic disorders and reduces inducible ventricular arrhythmias in rats with experimental myocardial infarction , 2016, BMC Cardiovascular Disorders.

[59]  G. Leoncini,et al.  Increased urine semaphorin-3A is associated with renal damage in hypertensive patients with chronic kidney disease: a nested case–control study , 2015, Journal of Nephrology.

[60]  Manman Tian,et al.  [The early diagnostic value of urinary Sema3A for ICU adult patients with acute kidney injury]. , 2015, Zhonghua yi xue za zhi.

[61]  Feiran Wang,et al.  Decreased semaphorin 3A expression is associated with a poor prognosis in patients with epithelial ovarian carcinoma. , 2015, International journal of molecular medicine.

[62]  D. Rimar,et al.  Semaphorin 3A: an immunoregulator in systemic sclerosis , 2015, Rheumatology International.

[63]  H. Rabb,et al.  Immune cells in experimental acute kidney injury , 2015, Nature Reviews Nephrology.

[64]  D. Siegel,et al.  Semaphorin3a Promotes Advanced Diabetic Nephropathy , 2014, Diabetes.

[65]  F. Luft.  Semaphorin-3A is a repulsive but attractive renal guidance cue to therapy , 2014, Journal of Molecular Medicine.

[66]  G. Ramesh,et al.  Netrin-1 and Semaphorin 3A Predict the Development of Acute Kidney Injury in Liver Transplant Patients , 2014, PloS one.

[67]  R. Gansevoort,et al.  Urinary semaphorin 3A correlates with diabetic proteinuria and mediates diabetic nephropathy and associated inflammation in mice , 2014, Journal of Molecular Medicine.

[68]  N. Weintraub,et al.  Semaphorin 3A inactivation suppresses ischemia-reperfusion-induced inflammation and acute kidney injury. , 2014, American journal of physiology. Renal physiology.

[69]  K. Yokote,et al.  Cell biology of diabetic nephropathy: Roles of endothelial cells, tubulointerstitial cells and podocytes , 2014, Journal of diabetes investigation.

[70]  A. Tufro.  Semaphorin3a signaling, podocyte shape, and glomerular disease , 2014, Pediatric Nephrology.

[71]  K. Reidy,et al.  Excess podocyte semaphorin-3A leads to glomerular disease involving plexinA1-nephrin interaction. , 2013, The American journal of pathology.

[72]  C. Krawczeski,et al.  Semaphorin 3A Is a New Early Diagnostic Biomarker of Experimental and Pediatric Acute Kidney Injury , 2013, PloS one.

[73]  Y. Goshima,et al.  Decreased Semaphorin3A expression correlates with disease activity and histological features of rheumatoid arthritis , 2013, BMC Musculoskeletal Disorders.

[74]  H. Okano,et al.  The Semaphorin 3A Inhibitor SM-345431 Accelerates Peripheral Nerve Regeneration and Sensitivity in a Murine Corneal Transplantation Model , 2012, PloS one.

[75]  M. Z. Cader,et al.  Neuropilins lock secreted semaphorins onto plexins in a ternary signaling complex , 2012, Nature Structural &Molecular Biology.

[76]  E. Toubi,et al.  Semaphorin 3A – a marker for disease activity and a potential putative disease-modifying treatment in systemic lupus erythematosus , 2012, Lupus.

[77]  E. Sabo,et al.  Human CD19(+)CD25(high) B regulatory cells suppress proliferation of CD4(+) T cells and enhance Foxp3 and CTLA-4 expression in T-regulatory cells. , 2012, Autoimmunity reviews.

[78]  J. Kellum,et al.  AKI in the ICU: definition, epidemiology, risk stratification, and outcomes. , 2012, Kidney international.

[79]  T. Sugaya,et al.  Evaluation of new acute kidney injury biomarkers in a mixed intensive care unit* , 2011, Critical care medicine.

[80]  M. Cooper,et al.  Pathogenesis of diabetic nephropathy , 2011, Journal of diabetes investigation.

[81]  E. Sabo,et al.  The involvement of immune semaphorins and neuropilin-1 in lupus nephritis , 2011, Lupus.

[82]  K. Reidy,et al.  Semaphorins in kidney development and disease: modulators of ureteric bud branching, vascular morphogenesis, and podocyte-endothelial crosstalk , 2011, Pediatric Nephrology.

[83]  H. Velázquez,et al.  Podocyte vascular endothelial growth factor (Vegf164) overexpression causes severe nodular glomerulosclerosis in a mouse model of type 1 diabetes , 2011, Diabetologia.

[84]  C. Sette,et al.  Pharmacological inhibition of TLR9 activation blocks autoantibody production in human B cells from SLE patients. , 2010, Rheumatology.

[85]  S. Akira,et al.  TLR9 and TLR4 are required for the development of autoimmunity and lupus nephritis in pristane nephropathy. , 2010, Journal of autoimmunity.

[86]  Wa Shen,et al.  Semaphorin3a regulates endothelial cell number and podocyte differentiation during glomerular development , 2009, Development.

[87]  S. Šatkauskas,et al.  The many faces of semaphorins: from development to pathology , 2009, Cellular and Molecular Life Sciences.

[88]  F. Grenier,et al.  Urine NGAL predicts severity of acute kidney injury after cardiac surgery: a prospective study. , 2008, Clinical journal of the American Society of Nephrology : CJASN.

[89]  C. Woda,et al.  Semaphorin3a inhibits ureteric bud branching morphogenesis , 2008, Mechanisms of Development.

[90]  F. Guan,et al.  Semaphorin3a disrupts podocyte foot processes causing acute proteinuria. , 2008, Kidney international.

[91]  A. Kolodkin,et al.  Semaphorin regulation of cellular morphology. , 2007, Annual review of cell and developmental biology.

[92]  C. Edelstein,et al.  Urinary IL-18 is an early predictive biomarker of acute kidney injury after cardiac surgery. , 2006, Kidney international.

[93]  F. Guan,et al.  Autocrine class 3 semaphorin system regulates slit diaphragm proteins and podocyte survival. , 2006, Kidney international.

[94]  K. Kikuchi,et al.  Xanthofulvin, a novel semaphorin inhibitor produced by a strain of Penicillium. , 2003, The Journal of antibiotics.

[95]  E. Neilson,et al.  Evidence that fibroblasts derive from epithelium during tissue fibrosis. , 2002, The Journal of clinical investigation.

[96]  M. Poo,et al.  Plexins Are a Large Family of Receptors for Transmembrane, Secreted, and GPI-Anchored Semaphorins in Vertebrates , 1999, Cell.

[97]  Alex L Kolodkin,et al.  Neuropilin Is a Semaphorin III Receptor , 1997, Cell.

[98]  D. Raible,et al.  Collapsin: A protein in brain that induces the collapse and paralysis of neuronal growth cones , 1993, Cell.

[99]  M. Kiriakidou,et al.  Systemic Lupus Erythematosus , 1991, Annals of Internal Medicine.

[100]  M. Steffes,et al.  Renal histologic changes in diabetes mellitus. , 1990, Seminars in nephrology.

[101]  Jonathan A. Raper,et al.  The enrichment of a neuronal growth cone collapsing activity from embryonic chick brain , 1990, Neuron.

[102]  Karolina Sterzyńska,et al.  Semaphorin 3A (SEMA3A), protocadherin 9 (PCdh9), and S100 calcium binding protein A3 (S100A3) as potential biomarkers of carcinogenesis and chemoresistance of different neoplasms, including ovarian cancer - review of literature. , 2019, Ginekologia polska.

[103]  M. Kretzler,et al.  OP-NDTJ180031 1942..2019 , 2018 .

[104]  J. R. Terman,et al.  Semaphorins and their Signaling Mechanisms. , 2017, Methods in molecular biology.

[105]  A. Tufro.  Podocyte Shape Regulation by Semaphorin 3A and MICAL-1. , 2017, Methods in molecular biology.

[106]  M. Nangaku,et al.  Repulsive guidance cue semaphorin 3A in urine predicts the progression of acute kidney injury in adult patients from a mixed intensive care unit. , 2014, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[107]  Incidence of end-stage renal disease attributed to diabetes among persons with diagnosed diabetes --- United States and Puerto Rico, 1996-2007. , 2010, MMWR. Morbidity and mortality weekly report.

[108]  T. Takahashi.  [Erythematosus]. , 1971, Nihon rinsho. Japanese journal of clinical medicine.

[109]  D. Perazzo,et al.  [Systemic lupus erythematosus]. , 1955, Prensa medica argentina.